Capricor Therapeutics Inc
NASDAQ:CAPR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.56
21.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Capricor Therapeutics Inc
Wall Street
Price Targets
CAPR Price Targets Summary
Capricor Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CAPR
is 42.11 USD
with a low forecast of 25.25 USD and a high forecast of 80.85 USD.
CAPR Last Price Targets
Capricor Therapeutics Inc
The latest public price target was made on Oct 21, 2024 by
Edward Tenthoff
from
Piper Sandler
,
who expects
CAPR
stock to
rise by 150%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Edward Tenthoff
Piper Sandler
|
35
USD
Upside 150% |
2 months ago
Oct 21, 2024
|
Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight
StreetInsider
|
Leland Gershall
Oppenheimer
|
43
USD
Upside 207% |
2 months ago
Oct 14, 2024
|
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
StreetInsider
|
|
Jason McCarthy
Maxim Group
|
25
USD
Upside 78% |
3 months ago
Sep 25, 2024
|
Capricor Therapeutics price target raised to $25 from $12 at Maxim
TheFly
|
|
Joseph Pantginis
H.C. Wainwright
|
40
USD
Upside 186% |
3 months ago
Sep 25, 2024
|
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
StreetInsider
|
|
Leland Gershall
Oppenheimer
|
15
USD
Upside 7% |
3 months ago
Sep 17, 2024
|
Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer
StreetInsider
|
|
Leland Gershall
Oppenheimer
|
14
USD
Downside 0% |
7 months ago
May 16, 2024
|
Oppenheimer Starts Capricor Therapeutics (CAPR) at Outperform
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CAPR's stock price target?
Price Target
42.11
USD
According to Wall Street analysts, the average 1-year price target for
CAPR
is 42.11 USD
with a low forecast of 25.25 USD and a high forecast of 80.85 USD.
What is Capricor Therapeutics Inc's Revenue forecast?
Projected CAGR
63%
For the last 8 years the
compound annual growth rate for
Capricor Therapeutics Inc's revenue is
21%.
The projected
CAGR
for the next 4 years is
63%.
You don't have any saved screeners yet
